LivaNova PLC (LIVN) vs. Its Rivals Head-To-Head Contrast

LivaNova PLC (NASDAQ: LIVN) is one of 91 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its competitors? We will compare LivaNova PLC to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, dividends, risk and profitability.

Institutional & Insider Ownership

82.3% of LivaNova PLC shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 0.3% of LivaNova PLC shares are held by company insiders. Comparatively, 11.8% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for LivaNova PLC and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova PLC 1 2 4 0 2.43
LivaNova PLC Competitors 197 1207 2643 92 2.64

LivaNova PLC currently has a consensus price target of $76.00, indicating a potential downside of 7.05%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.51%. Given LivaNova PLC’s competitors stronger consensus rating and higher probable upside, analysts clearly believe LivaNova PLC has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares LivaNova PLC and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
LivaNova PLC $1.21 billion -$62.78 million 69.88
LivaNova PLC Competitors $1.05 billion $129.96 million 205.80

LivaNova PLC has higher revenue, but lower earnings than its competitors. LivaNova PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

LivaNova PLC has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, LivaNova PLC’s competitors have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.

Profitability

This table compares LivaNova PLC and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova PLC 4.63% 9.33% 6.82%
LivaNova PLC Competitors -124.52% -35.86% -9.50%

Summary

LivaNova PLC competitors beat LivaNova PLC on 8 of the 13 factors compared.

About LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

What are top analysts saying about LivaNova PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LivaNova PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit